These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 30442679)

  • 1. Cerebral cavernous malformations form an anticoagulant vascular domain in humans and mice.
    Lopez-Ramirez MA; Pham A; Girard R; Wyseure T; Hale P; Yamashita A; Koskimäki J; Polster S; Saadat L; Romero IA; Esmon CT; Lagarrigue F; Awad IA; Mosnier LO; Ginsberg MH
    Blood; 2019 Jan; 133(3):193-204. PubMed ID: 30442679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations.
    Zhu Y; Wu Q; Xu JF; Miller D; Sandalcioglu IE; Zhang JM; Sure U
    Neurosurg Focus; 2010 Sep; 29(3):E1. PubMed ID: 20809750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caveolae-mediated Tie2 signaling contributes to CCM pathogenesis in a brain endothelial cell-specific Pdcd10-deficient mouse model.
    Zhou HJ; Qin L; Jiang Q; Murray KN; Zhang H; Li B; Lin Q; Graham M; Liu X; Grutzendler J; Min W
    Nat Commun; 2021 Jan; 12(1):504. PubMed ID: 33495460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral cavernous malformations arise independent of the heart of glass receptor.
    Zheng X; Riant F; Bergametti F; Myers CD; Tang AT; Kleaveland B; Pan W; Yang J; Tournier-Lasserve E; Kahn ML
    Stroke; 2014 May; 45(5):1505-1509. PubMed ID: 24643410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct cellular roles for PDCD10 define a gut-brain axis in cerebral cavernous malformation.
    Tang AT; Sullivan KR; Hong CC; Goddard LM; Mahadevan A; Ren A; Pardo H; Peiper A; Griffin E; Tanes C; Mattei LM; Yang J; Li L; Mericko-Ishizuka P; Shen L; Hobson N; Girard R; Lightle R; Moore T; Shenkar R; Polster SP; Rödel CJ; Li N; Zhu Q; Whitehead KJ; Zheng X; Akers A; Morrison L; Kim H; Bittinger K; Lengner CJ; Schwaninger M; Velcich A; Augenlicht L; Abdelilah-Seyfried S; Min W; Marchuk DA; Awad IA; Kahn ML
    Sci Transl Med; 2019 Nov; 11(520):. PubMed ID: 31776290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation.
    Jenny Zhou H; Qin L; Zhang H; Tang W; Ji W; He Y; Liang X; Wang Z; Yuan Q; Vortmeyer A; Toomre D; Fuh G; Yan M; Kluger MS; Wu D; Min W
    Nat Med; 2016 Sep; 22(9):1033-1042. PubMed ID: 27548575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroinflammation Plays a Critical Role in Cerebral Cavernous Malformation Disease.
    Lai CC; Nelsen B; Frias-Anaya E; Gallego-Gutierrez H; Orecchioni M; Herrera V; Ortiz E; Sun H; Mesarwi OA; Ley K; Gongol B; Lopez-Ramirez MA
    Circ Res; 2022 Nov; 131(11):909-925. PubMed ID: 36285625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerebral cavernous malformations proteins inhibit Rho kinase to stabilize vascular integrity.
    Stockton RA; Shenkar R; Awad IA; Ginsberg MH
    J Exp Med; 2010 Apr; 207(4):881-96. PubMed ID: 20308363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single-center study on 140 patients with cerebral cavernous malformations: 28 new pathogenic variants and functional characterization of a PDCD10 large deletion.
    Nardella G; Visci G; Guarnieri V; Castellana S; Biagini T; Bisceglia L; Palumbo O; Trivisano M; Vaira C; Scerrati M; Debrasi D; D'Angelo V; Carella M; Merla G; Mazza T; Castori M; D'Agruma L; Fusco C
    Hum Mutat; 2018 Dec; 39(12):1885-1900. PubMed ID: 30161288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and Purification of Mouse Brain Endothelial Cells to Study Cerebral Cavernous Malformation Disease.
    Hale P; Soliman SI; Sun H; Lopez-Ramirez MA
    Methods Mol Biol; 2020; 2152():139-150. PubMed ID: 32524550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombospondin1 (TSP1) replacement prevents cerebral cavernous malformations.
    Lopez-Ramirez MA; Fonseca G; Zeineddine HA; Girard R; Moore T; Pham A; Cao Y; Shenkar R; de Kreuk BJ; Lagarrigue F; Lawler J; Glass CK; Awad IA; Ginsberg MH
    J Exp Med; 2017 Nov; 214(11):3331-3346. PubMed ID: 28970240
    [No Abstract]   [Full Text] [Related]  

  • 12. Cerebral cavernous malformations arise from endothelial gain of MEKK3-KLF2/4 signalling.
    Zhou Z; Tang AT; Wong WY; Bamezai S; Goddard LM; Shenkar R; Zhou S; Yang J; Wright AC; Foley M; Arthur JS; Whitehead KJ; Awad IA; Li DY; Zheng X; Kahn ML
    Nature; 2016 Apr; 532(7597):122-6. PubMed ID: 27027284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Description of Two Families with New Mutations in Familial Cerebral Cavernous Malformations Genes.
    Iruzubieta P; Campo-Caballero D; Equiza J; Albajar I; Sulibarría N; Sáez R; Andrés N; Mondragón E; Zulaica M; de Arce A; Urtasun M; López de Munain A
    J Stroke Cerebrovasc Dis; 2021 Dec; 30(12):106130. PubMed ID: 34597987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. mTORC1 Signaling in Brain Endothelial Progenitors Contributes to CCM Pathogenesis.
    Min W; Qin L; Zhang H; López-Giráldez F; Jiang N; Kim Y; Mohan VK; Su M; Murray KN; Grutzendler J; Zhou JH
    Circ Res; 2024 Aug; 135(4):e94-e113. PubMed ID: 38957991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Genetic Features of Cerebral Cavernous Malformations (CCM) Patients: An Overall View from Genes to Endothelial Cells.
    Riolo G; Ricci C; Battistini S
    Cells; 2021 Mar; 10(3):. PubMed ID: 33810005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in 2 distinct genetic pathways result in cerebral cavernous malformations in mice.
    Chan AC; Drakos SG; Ruiz OE; Smith AC; Gibson CC; Ling J; Passi SF; Stratman AN; Sacharidou A; Revelo MP; Grossmann AH; Diakos NA; Davis GE; Metzstein MM; Whitehead KJ; Li DY
    J Clin Invest; 2011 May; 121(5):1871-81. PubMed ID: 21490399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of CCM Phenotype by a Human Microvascular Endothelial Model.
    Delle Monache S; Retta SF
    Methods Mol Biol; 2020; 2152():131-137. PubMed ID: 32524549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β1 integrin monoclonal antibody treatment ameliorates cerebral cavernous malformations.
    McCurdy S; Lin J; Shenkar R; Moore T; Lightle R; Faurobert E; Lopez-Ramirez MA; Awad I; Ginsberg MH
    FASEB J; 2022 Dec; 36(12):e22629. PubMed ID: 36349990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KLF4 is a key determinant in the development and progression of cerebral cavernous malformations.
    Cuttano R; Rudini N; Bravi L; Corada M; Giampietro C; Papa E; Morini MF; Maddaluno L; Baeyens N; Adams RH; Jain MK; Owens GK; Schwartz M; Lampugnani MG; Dejana E
    EMBO Mol Med; 2016 Jan; 8(1):6-24. PubMed ID: 26612856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Astrocytes propel neurovascular dysfunction during cerebral cavernous malformation lesion formation.
    Lopez-Ramirez MA; Lai CC; Soliman SI; Hale P; Pham A; Estrada EJ; McCurdy S; Girard R; Verma R; Moore T; Lightle R; Hobson N; Shenkar R; Poulsen O; Haddad GG; Daneman R; Gongol B; Sun H; Lagarrigue F; Awad IA; Ginsberg MH
    J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34043589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.